Biotech Values

[BTH]

Yea, the valuation is certainly low, thats for sure.

Maybe they will simply get lucky with their FGFR inhibitor. Ariad's ponatinib is beginning a trial in squamous cell lung cancer being run by docs at Dana Farber shortly (as you know, Dana Farber aint no joke). There is a rationale for FGFR in this indication. Can someone email or call that moron Pucci at ArQule so he doesn't enroll every other cancer indication EXCEPT that of squamous cell lung cancer????